Summary Background In the Safety and Efficacy of Nintedanib in Systemic Sclerosis
(SENSCIS) trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) in …

Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …

Objective. Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic
pulmonary fibrosis (IPF). The pathological pathways involved in fibrogenesis in IPF and …

Objectives To characterise the safety and tolerability of nintedanib and the dose adjustments
used to manage adverse events in patients with systemic sclerosis-associated interstitial …

Objective Using data from the SENSCIS trial, these analyses were undertaken to assess the
effects of nintedanib versus placebo in subgroups of patients with systemic sclerosis …

Nintedanib (Ofev™), an oral triple kinase inhibitor targeting pro-fibrotic pathways, has been
used for treatment of idiopathic pulmonary fibrosis (IPF). Based on positive results from …

Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in
patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding …

Abstract Background Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder.
Interstitial lung disease (ILD) is common in SSc, occurring in 35–52% of patients and …

Systemic sclerosis (SSc) is a progressive and often devastating disease characterized by
autoimmune dysfunction, vasculopathy, and fibrosis. Interstitial lung disease (ILD) is …

Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …